Poland· PL-100501660

Pazopanib Sandoz

A pazopanib product containing pazopanibum, registered in Poland by Sandoz Polska Sp. z o.o.. The same ATC class is registered in 14 of our 19 countries.

ATC L01EX03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedPazopanib SandozATCL01EX03REGISTER NO.PL-100501660PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Pazopanib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EX03 (pazopanib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Pazopanib · ATC L01EX03

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of pazopanib costs, country by country.

Normalised to the WHO defined daily dose (0.8 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Pazopanib · price per daily dose (0.8 g)

USD · FX 28 Sept 2026

  • CH Switzerland$87.69
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Pazopanibum
Manufacturer
Sandoz Polska Sp. z o.o.
Country
Poland (PL)
ATC code
L01EX03
ATC class
Pazopanib
Defined daily dose
0.8 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991578213

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

593 interactions on record for pazopanib.

Graded by severity as the source publishes them — 155 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Pazopanib · interactions on record

593 records

  • 155 severe
  • 428 moderate
  • 10 minor

Most severe, free to view

  • CimetidineA02BA01severe
  • RanitidineA02BA02severe
  • FamotidineA02BA03severe
  • NizatidineA02BA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pazopanib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pazopanib products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Pazopanib Devatis
  • Belgium · Pazopanib Accord, Pazopanib Eg
  • Bulgaria · Алуниб, Пазопаниб G.L. Pharma
  • Cyprus · Pazopanib Sapiens, Pazorem
  • Czechia · Pazopanib Accord, Pazopanib Sandoz
  • Germany · Pazopanib Al, Pazopanib Beta
  • Denmark · Pazopanib Accord, Pazopanib Glenmark
  • Estonia · Pazopanib Accord, Pazopanib Teva
  • Spain · Pazopanib Accord, Pazopanib Dr. Reddys
  • Finland · Pazopanib Accord, Pazopanib Glenmark
  • France · Pazopanib Accord, Pazopanib Biogaran
  • United Kingdom (Northern Ireland) · Pazopanib Accord, Pazopanib Accord Healthcare
  • Greece · Pazopanib Accord, Pazopanib Stada
  • Croatia · Pazopanib Accord, Pazopanib Frontier
  • Hungary · Pazopanib Accord, Pazopanib G.L. Pharma
  • Ireland · Pazopanib Accord, Pazopanib Reddy
  • Iceland · Pazopanib Adalvo, Pazopanib Stada
  • Italy · Pazopanib Accord, Pazopanib Dr. Reddy’s
  • Liechtenstein · Votrient
  • Lithuania · Pazopanib Accord, Pazopanib Auxilia
  • Luxembourg · Pazopanib Eg, Pazopanib Pazopanib Eg
  • Latvia · Pazopanib Accord, Pazopanib Teva
  • Malta · Pazopanib Pharmacare, Pazopanib Pharos
  • Netherlands · Pazopanib Accord, Pazopanib Cf
  • Norway · Pazopanib Accord, Pazopanib Glenmark
  • Portugal · Pazopanib Accord, Pazopanib Bluepharma
  • Romania · Pazopanib Accord, Pazopanib Dr. Reddys
  • Sweden · Pazopanib Accord, Pazopanib Glenmark
  • Slovenia · Pazopanib Accord, Pazopanib Teva
  • Slovakia · Pazopanib Accord, Pazopanib G.L. Pharma

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d50ee378-dd00-4d8e-8735-d1322b485a98
GET /v1/drugs/d50ee378-dd00-4d8e-8735-d1322b485a98?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "200 mg",
  "packaging": "05909991578213 ¦ Rp ¦ 162544\n30 tabl.",
  "substance": "Pazopanibi hydrochloridum 216.7 mg",
  "common_name": "Pazopanibum",
  "pl_product_id": "100501660",
  "pozwolenie_nr": "29126",
  "auth_procedure": "MRP",
  "authorisation_validity": "2030-06-12"
}

See everything about pazopanib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.